Broker's call: Glenmark Pharma (Sell)

| Updated on February 18, 2021

Prabhudas Lilladher

Glenmark Pharma (Sell)

Target: ₹446

CMP: ₹492

We reduce our earnings estimate by one per cent for FY22/23 as we lower our growth projections for semi-regulated market. Q3 FY21 earnings were in line with our estimates led by growth in India formulations and cost rationalisation.

India formulations grew 12 per cent y-o-y while adjusted growth (ex-Favipiravir) in lower single digit. ICHNOS Sciences’ fund-raising is to get further delayed.

Glenmark Pharmaceuticals is our top sell idea given: 1) US derma portfolio (35 per cent of US revenue) would lag growth due to competition; 2) Has thin US product pipeline with only 47 pending (Abbreviated New Drug Application) ANDAs plus guidance of 8-10 new launches in FY21; 3) 60-65 per cent of R&D spends towards hardly visible specialty products; 4) Insignificant EBITDA contribution from new Monroe facility even with qualitative approvals (due to higher operating cost); 5) Appreciating USD (against rupee) may increase debt (current net debt ₹3,640 crore) and 6) Muted growth in core domestic formulations.

We maintain ‘Sell’ and reduce our TP to ₹446 (earlier ₹449) based on 12x PE (Unchanged) on FY23E EPS of ₹37.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 18, 2021
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.